Jump to content

May 2015: "Clinical Pharmacogenetics Implementation Consortium Guideline" - SSRI


[La...]

Recommended Posts

If you click on the "Author Information" link under the title of this abstract, you'll see how many educational institutions in the US -- plus a few others in Canada, Germany and Spain -- are participating in this guideline preparation. The abstract is called "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors."

 

From the abstract:

 

"CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs thereby affecting drug efficacy and safety."

 

If you're taking an SSRI or considering it, you might be interesting in the topic of "pharmacogenetics". There's more info available online but for this particular abstract, have a look here:

 

http://www.ncbi.nlm.nih.gov/pubmed/25974703

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...